WALTHAM,
Mass., Nov. 22, 2022 /PRNewswire/
-- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company
founded with a mission to discover, develop and commercialize
innovative first-in-class medicines that meet significant unmet
medical needs, today announced that management will participate in
a fireside discussion at the 34th Annual Piper Sandler
Healthcare Conference on Thursday, December
1, 2022, at 10:00 a.m. ET in
New York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 30 days
following the conference.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and
commercialize innovative first-in-class medicines that meet
significant unmet medical needs. Ardelyx's first approved product,
IBSRELA® (tenapanor) is available in the
United States and Canada.
Ardelyx is developing XPHOZAH® (tenapanor), a novel product
candidate to control serum phosphorus in adult patients with CKD on
dialysis, which has completed three successful Phase 3 trials.
Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the
potential treatment of elevated serum potassium, or hyperkalemia, a
problem among certain patients with kidney and/or heart disease and
an early-stage program in metabolic acidosis, a serious electrolyte
disorder in patients with CKD. Ardelyx has established agreements
with Kyowa Kirin in Japan, Fosun
Pharma in China and Knight
Therapeutics in Canada for the
development and commercialization of tenapanor in their respective
territories. For more information, please visit
https://ardelyx.com/ and connect with us on Twitter @Ardelyx,
LinkedIn and Facebook.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-34th-annual-piper-sandler-healthcare-conference-301684752.html
SOURCE Ardelyx